EUVIMEDEUVIMED entdecken
Open Access

Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells

Nghia Nguyen, Yu Min, Jennifer Rivière, Mark van der Garde, Sukhen Ghosh, Laura M Bartos, Matthias Brendel, Florian Bassermann, Ali Azhdarinia, Wolfgang A Weber, Katharina S Götze, Susanne Kossatz

Theranostics · 25.05.2025 · 15 (13) · 6497-6515

DOI: 10.7150/thno.113354 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, erschienen am 25.05.2025. Verfasst von Nghia Nguyen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, TUM University Hospital, School of Medicine and Health, Technical University Munich, Munich, Germany. Hauptthemen laut MEDLINE: Hematopoietic Stem Cells, Receptors, Somatostatin, Neuroendocrine Tumors, Radiopharmaceuticals. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Radiopharmaceutical therapy (RPT) has become an effective treatment option for neuroendocrine tumors (NETs) and castration-resistant prostate cancer and is in clinical development for many indications. One of the major advantages of theranostic RPT is that the distribution of radiopharmaceuticals in the human body can be imaged, and radiation doses to the patient's organs can be calculated. However, accurate dosimetry may be fundamentally limited by microscopic heterogeneity of radiopharmaceutical distribution.

Methods

We developed fluorescent analogs of somatostatin-receptor-subtype 2 (SSTR2) targeting Lutetium-177 labeled radiopharmaceuticals that are clinically used in patients with NETs and studied their uptake by hematopoietic stem and progenitor cells (HSPC) using flow cytometry and microscopy.

Results

Hematopoietic stem cells (HSCs) and multipotent progenitor cells (MPPs) showed high and specific SSTR2-ligand uptake, which was at similar levels as NET cells. Furthermore, they displayed a several-fold higher uptake of SSTR2-antagonists than of SSTR2-agonists. HSPC treatment with a 177Lu-labeled antagonist and agonist showed a stronger reduction of HSC proliferation by the antagonist. Due to the scarcity of HSCs and MPPs, their contribution to total bone marrow uptake of SSTR2-radiopharmaceuticals is negligible in imaging-based dosimetry. This likely explains why SSTR2-antagonists caused pancytopenia in clinical trials despite safe dosimetry estimates.

Conclusion

Target expression heterogeneity can lead to underestimation of radiopharmaceutical toxicity and should be considered when designing clinical trials for new radiopharmaceuticals. The implications of our findings go beyond SSTR2-targeted radiopharmaceuticals and suggest more generally that first-in-human studies should not only be guided by radiation dosimetry but should also include careful escalation of the administered therapeutic activity. Our multimodal ligand design is modular and can be applied to other peptide or protein-based radiopharmaceuticals to study cellular distribution and potential bone marrow uptake prior to clinical testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem CellsReceptors, SomatostatinNeuroendocrine TumorsRadiopharmaceuticalsHumansRadioisotopesLutetiumAnimalsMiceTheranostic Nanomedicine

Stichwörter der Autor:innen

Radiopharmaceutical therapy (RPT)SSTR2dosimetry.hematopoietic stem cellshematotoxicitytheranostics

Substanzen

Receptors, SomatostatinRadiopharmaceuticalsRadioisotopesLutetiumLutetium-177

Autor:innen und Institutionen

  • Department of Nuclear Medicine, TUM University Hospital, School of Medicine and Health, Technical University Munich, Munich, Germany.
  • Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, Technical University Munich, Munich, Germany.
  • Department of Medicine III, TUM University Hospital, School of Medicine and Health, Technical University of Munich, Munich, Germany.
  • The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, United States of America.
  • Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.
  • Bavarian Cancer Research Center (BZKF), Munich, Germany.

Zitieren

APA

Nguyen, N., Min, Y., Rivière, J., van der Garde, M., Ghosh, S., Bartos, L. M., Brendel, M., Bassermann, F., Azhdarinia, A., Weber, W. A., Götze, K. S., & Kossatz, S. (2025). Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells. Theranostics, 15(13), 6497-6515. https://doi.org/10.7150/thno.113354

Vancouver

Nguyen N, Min Y, Rivière J, van der Garde M, Ghosh S, Bartos LM, et al. Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells. Theranostics. 2025;15(13):6497-6515. doi:10.7150/thno.113354

BibTeX
@article{Nguyen2025,
  author = {Nguyen, Nghia and Min, Yu and Rivière, Jennifer and van der Garde, Mark and Ghosh, Sukhen and Bartos, Laura M and Brendel, Matthias and Bassermann, Florian and Azhdarinia, Ali and Weber, Wolfgang A and Götze, Katharina S and Kossatz, Susanne},
  title = {Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells},
  journal = {Theranostics},
  year = {2025},
  volume = {15},
  number = {13},
  pages = {6497--6515},
  doi = {10.7150/thno.113354}
}
Kostenlos starten →